CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CUMBERLAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.70−0.48 (-6.69%)
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
CUMBERLAND PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vibativ | $12.94M | $13.90M | $9.48M | $10.37M | $8.80M | $8.55M | $7.16M | $7.12M | $8.88M | $8.57M | $8.81M | – | 41.4% | +47.0% |
| Sancuso | $11.28M | $12.58M | $11.91M | $11.00M | $10.36M | $9.43M | $9.01M | $8.98M | $8.31M | $8.04M | $8.10M | – | 36.1% | +8.8% |
| Kristalose | $6.35M | $8.04M | $10.54M | $11.80M | $14.25M | $15.60M | $15.32M | $14.60M | $14.86M | $14.86M | $15.98M | – | 20.3% | -55.5% |
| Caldolor | $4.20M | $4.32M | $4.66M | $5.14M | $5.54M | $4.80M | $4.96M | $4.60M | $4.49M | $4.87M | $4.33M | – | 13.4% | -24.1% |
| Other revenue | $881.52K | $1.15M | $4.13M | $4.16M | $4.48M | $4.20M | $1.33M | – | – | – | – | – | 2.8% | -80.3% |
| Acetadote | $351.91K | $408.79K | $508.17K | $482.00K | $406.78K | $256.63K | $185.18K | $163.66K | $262.34K | $369.11K | $458.76K | – | 1.1% | -13.5% |
| Acetadote | – | – | – | – | – | – | – | – | – | – | – | $603.43K | – | – |
| Caldolor | – | – | – | – | – | – | – | – | – | – | – | $5.07M | – | – |
| Kristalose | – | – | – | – | – | – | – | – | – | – | – | $16.10M | – | – |
| Sancuso | – | – | – | – | – | – | – | – | – | – | – | $8.19M | – | – |
By region
From the segment and revenue-disaggregation notes of Cumberland Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.